Fotivda (Tivozanib)
VEGF Receptor Tyrosine Kinase Inhibitor for Advanced Kidney Cancer
Quick Facts About Fotivda
Key Takeaways About Fotivda
- Targeted cancer therapy: Fotivda selectively blocks VEGF receptors 1, 2, and 3 to cut off blood supply to tumours, slowing the growth and spread of advanced kidney cancer
- Cyclical dosing schedule: Taken as one capsule once daily for 21 days followed by a 7-day rest period, repeating in 4-week cycles
- Hypertension is the most common side effect: Blood pressure must be monitored regularly throughout treatment, and antihypertensive medication may be needed
- Not safe during pregnancy: Both male and female patients must use effective contraception during treatment and for one month after the final dose
- Avoid St. John’s Wort: Co-administration with Hypericum perforatum is contraindicated as it significantly reduces tivozanib effectiveness
What Is Fotivda and What Is It Used For?
Fotivda (tivozanib) is a targeted anticancer medicine that inhibits the growth of new blood vessels feeding tumours. It is used to treat adults with advanced renal cell carcinoma (kidney cancer) when prior cytokine therapy has not been used or when previous systemic treatments have not stopped the disease from progressing.
The active substance in Fotivda is tivozanib, a potent and highly selective protein kinase inhibitor. Tivozanib specifically targets the vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which play a central role in the process of angiogenesis – the formation of new blood vessels. Tumours, including kidney cancers, require a robust blood supply to grow and spread throughout the body. They achieve this by releasing vascular endothelial growth factor (VEGF), a signalling protein that stimulates the formation of new blood vessels from existing ones.
By blocking the effect of VEGF on its receptors, tivozanib prevents the development of new blood vessels that would otherwise supply the tumour with oxygen and nutrients. This anti-angiogenic action reduces blood supply to the cancer, which slows tumour growth and limits its ability to metastasise (spread to other parts of the body). Unlike many other tyrosine kinase inhibitors used in oncology, tivozanib is particularly selective for VEGF receptors, which is believed to contribute to a more favourable tolerability profile with fewer off-target effects.
Fotivda is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). Renal cell carcinoma is the most common type of kidney cancer, accounting for approximately 85–90% of all kidney malignancies. Advanced RCC refers to cancer that has spread beyond the kidney or cannot be treated with surgery. Fotivda may be used as a first-line treatment (when prior cytokine therapies such as interferon-alfa or interleukin-2 have not been used) or in subsequent lines of therapy when other systemic treatments have failed to control the disease.
The efficacy of tivozanib in advanced RCC was demonstrated in the pivotal TIVO-3 phase III randomised controlled trial, which compared tivozanib with sorafenib in patients who had received two or three prior systemic therapies. The trial showed a statistically significant improvement in progression-free survival (PFS) for tivozanib compared with sorafenib (5.6 months vs 3.9 months; hazard ratio 0.73, p=0.016). These results, along with earlier phase III data (TIVO-1 trial), supported the regulatory approval of Fotivda by the European Medicines Agency (EMA).
Fotivda was first authorised in the European Union in 2017. It is marketed by Recordati and represents an important treatment option in the continually evolving landscape of targeted therapy for kidney cancer. The unique cyclical dosing schedule (3 weeks on, 1 week off) was designed to help manage certain side effects, particularly hypertension, by allowing recovery during the treatment-free week.
What Should You Know Before Taking Fotivda?
Before starting Fotivda, tell your doctor about all your medical conditions, particularly high blood pressure, heart problems, blood clots, liver disease, thyroid disorders, and any history of bleeding. Fotivda is contraindicated in patients allergic to tivozanib and must not be taken with St. John’s Wort.
Contraindications
You should not take Fotivda if either of the following applies to you:
- Allergy to tivozanib or any of the other ingredients in the capsule (including mannitol, magnesium stearate, gelatin, titanium dioxide, indigo carmine, yellow iron oxide, shellac, or propylene glycol)
- Concurrent use of St. John’s Wort (Hypericum perforatum), an herbal remedy sometimes used for mild depression and anxiety. St. John’s Wort is a potent CYP3A4 inducer that can significantly reduce tivozanib blood levels, potentially rendering the treatment ineffective
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking Fotivda if you have or have had any of the following conditions. Your doctor will need to carefully weigh the risks and benefits of treatment and may require additional monitoring throughout your therapy:
High blood pressure (hypertension): Fotivda can increase your blood pressure. This is the most commonly reported side effect and can be severe. Your doctor will monitor your blood pressure regularly before and during treatment. If your blood pressure becomes too high, your doctor may prescribe antihypertensive medication, reduce your Fotivda dose, or temporarily or permanently discontinue treatment. If you already take medication for high blood pressure, your doctor will also monitor your blood pressure closely if the dose of Fotivda is reduced or treatment is paused.
Aneurysm or arterial dissection: Tell your doctor if you have or have ever had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall (arterial dissection), as VEGF pathway inhibitors may increase the risk of these events.
Blood clots (thromboembolic events): Treatment with Fotivda can increase the risk of developing blood clots. These clots may form in blood vessels and travel to block other vessels (thromboembolism). Tell your doctor if you have ever experienced blood clots in the lungs (pulmonary embolism), legs (deep vein thrombosis), eyes, or brain, or if you have had a stroke, transient ischaemic attack (TIA), heart attack, or have a history of high blood pressure, diabetes, major surgery, prolonged immobility, or heart failure.
Heart failure: Fotivda may affect heart function. Inform your doctor if you experience shortness of breath (dyspnoea) during exertion or when lying down, weakness, fatigue, swelling of the legs, ankles, or feet, reduced physical capacity, persistent cough, or wheezing with white or pink blood-tinged sputum. Your doctor will monitor for signs and symptoms of heart failure during treatment and may reduce the dose or discontinue Fotivda if necessary.
Heart rhythm abnormalities (arrhythmia): If you have or are being treated for abnormal heart rate or rhythm, your doctor will monitor your heart with electrocardiogram (ECG) recordings and may check blood levels of calcium, magnesium, and potassium during treatment.
Liver problems: Your doctor will regularly monitor your liver function with blood tests before and during Fotivda treatment. If you have liver impairment, your doctor may prescribe Fotivda less frequently (e.g. every other day).
Thyroid disorders: Fotivda can cause the thyroid gland to become underactive (hypothyroidism). Your doctor will monitor thyroid function with blood tests before and during treatment. If you are already taking medication for a thyroid condition, additional monitoring may be required.
- Severe headache, visual disturbances, confusion, or seizures (possible signs of posterior reversible encephalopathy syndrome – PRES)
- Sudden shortness of breath or swollen ankles (possible signs of heart failure)
- Severe abdominal pain, vomiting blood, coughing up blood, black stools, or blood in your urine (signs of serious bleeding)
- Severe abdominal pain with fever, chills, nausea, vomiting, or rectal bleeding (possible signs of gastrointestinal perforation or fistula)
Bleeding: Fotivda may increase the risk of bleeding. Contact your doctor immediately if you experience any bleeding problems, including painful swollen abdomen, vomiting blood, coughing up blood, black stools, blood in urine, headache, or changes in mental status.
Proteinuria: Your doctor will test your urine for protein at the beginning of and during treatment. Depending on the results, your doctor may reduce the dose or discontinue treatment temporarily or permanently.
Hand-foot skin reaction: If the skin on your hands or the soles of your feet becomes dry, cracked, scaly, or peeling, or if it stings or burns, tell your doctor. This condition is known as palmar-plantar erythrodysaesthesia (hand-foot syndrome). Your doctor will manage this condition and may adjust your dose as needed.
Wound healing: Your doctor may recommend temporarily stopping Fotivda if you need to undergo surgery, as the drug may impair wound healing.
Pregnancy and Breastfeeding
Do not take Fotivda if you are pregnant. Tivozanib may cause harm to the developing baby due to its mechanism of action (inhibition of blood vessel formation is critical for foetal development). If you are pregnant or suspect you may be pregnant, inform your doctor immediately. Your doctor will discuss the potential risks of Fotivda to you and your baby.
Both you and your partner must use effective contraception during treatment and for at least one month after the last dose. If you or your partner are using hormonal contraceptives (e.g. birth control pills, intrauterine devices, or patches), you must also use an additional barrier method of contraception throughout treatment and for one month after the final dose, because it is not known whether tivozanib may reduce the effectiveness of hormonal contraceptives.
Do not breastfeed during treatment with Fotivda, as it is not known whether tivozanib passes into breast milk. Talk to your doctor if you are currently breastfeeding before starting treatment.
Speak with your doctor if you are planning to have children, as Fotivda may affect fertility in both men and women.
Driving and Operating Machinery
Fotivda may cause side effects that affect your ability to drive or use machines. You may experience weakness, fatigue, or dizziness during treatment. If you experience any of these symptoms, do not drive or operate machinery until they resolve. Always discuss any concerns about driving with your doctor.
How Does Fotivda Interact with Other Drugs?
Fotivda interacts with several medications, including CYP3A4 inducers and inhibitors. St. John’s Wort is strictly contraindicated. Tell your doctor about all medications, herbal remedies, and over-the-counter products you are taking or plan to take.
Tivozanib can interact with other medications that affect or are affected by the same metabolic pathways. In particular, drugs that strongly induce the CYP3A4 enzyme can reduce tivozanib blood levels and may make the treatment less effective. Additionally, tivozanib may affect blood levels of certain other medications, including rosuvastatin. Your doctor will consider all your current medications when prescribing Fotivda and may need to adjust doses or change treatments accordingly.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| St. John’s Wort (Hypericum perforatum) | Herbal supplement | Strong CYP3A4 inducer that significantly reduces tivozanib blood levels | Contraindicated – must not be used with Fotivda |
| Rifampicin | Antibiotic (tuberculosis treatment) | Strong CYP3A4 inducer that substantially reduces tivozanib effectiveness | Avoid combination; doctor may change medication |
| Phenytoin / Carbamazepine | Anti-epileptic drugs | CYP3A4 inducers that reduce tivozanib blood levels | Doctor may change anti-epileptic medication or adjust doses |
| Phenobarbital | Anti-epileptic / barbiturate | CYP3A4 inducer that reduces tivozanib blood levels | Doctor may consider alternative treatments |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Dexamethasone | Corticosteroid | CYP3A4 inducer that may reduce tivozanib effectiveness; also used for immune suppression | Doctor may adjust dosing; monitor treatment response |
| Rosuvastatin | Cholesterol-lowering (statin) | Tivozanib may increase rosuvastatin blood levels, raising risk of side effects | Monitor for statin-related side effects (muscle pain); dose adjustment may be needed |
| Rifabutin / Rifapentin | Antibiotics (mycobacterial infections) | CYP3A4 inducers that may reduce tivozanib blood levels | Avoid if possible; monitor treatment response closely |
| Nafcillin | Antibiotic (penicillinase-resistant penicillin) | CYP3A4 inducer that may reduce tivozanib levels | Doctor may choose alternative antibiotic |
If you are taking medications for high blood pressure, be aware that Fotivda commonly causes hypertension as a side effect. Your doctor may need to adjust your antihypertensive medication doses accordingly. Additionally, if you are taking hormonal contraceptives, an additional barrier method of contraception should be used, as tivozanib may potentially affect the efficacy of hormonal birth control.
Always tell your doctor about any herbal medicines, dietary supplements, or over-the-counter products you are using. Some herbal products can interact with cancer medications in unexpected ways. St. John’s Wort in particular is strictly contraindicated with Fotivda and must not be taken at any point during treatment.
What Is the Correct Dosage of Fotivda?
The recommended dose of Fotivda is one 1,340 microgram capsule taken once daily for 21 consecutive days, followed by a 7-day treatment-free period. This 28-day cycle repeats for as long as the treatment continues to work and side effects remain manageable.
Always take Fotivda exactly as your doctor has instructed. Do not change the dose without consulting your doctor or pharmacist first. Fotivda capsules should be swallowed whole with a glass of water and can be taken with or without food. Do not chew, dissolve, or open the capsule before swallowing.
Adults – Standard Dose
Advanced Renal Cell Carcinoma
Standard dose: 1,340 micrograms (one capsule) once daily
Schedule: 21 days on treatment, followed by 7 days off (28-day cycle)
Your doctor will monitor you regularly and will continue treatment for as long as Fotivda is working and you are not experiencing unacceptable side effects. Treatment cycles are repeated continuously until disease progression or intolerable toxicity.
Reduced Dose
Dose Reduction for Side Effects
Reduced dose: 890 micrograms (one capsule) once daily
Schedule: 21 days on treatment, followed by 7 days off (28-day cycle)
If you experience severe side effects, your doctor may decide to temporarily interrupt treatment and/or reduce the dose from 1,340 micrograms to 890 micrograms daily. The same cyclical schedule applies.
Patients with Liver Impairment
If you have liver problems, your doctor may prescribe Fotivda at the standard strength (1,340 micrograms) but taken every other day instead of daily. This adjusted schedule accounts for the altered metabolism of tivozanib in patients with hepatic impairment and helps prevent excessive drug accumulation in the body.
Children and Adolescents
Fotivda is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of tivozanib have not been studied in this age group.
Missed Dose
If you miss a dose of Fotivda, do not take a replacement capsule. Simply take the next dose at the usual time. Do not take a double dose to make up for a forgotten one. Similarly, if you vomit after taking a dose, do not take a replacement capsule – wait until the next scheduled dose.
Overdose
If you have taken more than the prescribed dose (equivalent to more than one capsule daily), contact your doctor or emergency services immediately. An overdose of Fotivda increases the risk and severity of side effects, particularly dangerously high blood pressure. Seek immediate medical attention if you experience confusion, changes in mental status, or severe headache, as these may be symptoms of hypertensive crisis.
Stopping Treatment
Do not stop taking Fotivda unless your doctor tells you to do so. Stopping treatment on your own may allow the cancer to progress. If you have questions or concerns about continuing treatment, discuss them with your doctor, pharmacist, or oncology nurse.
What Are the Side Effects of Fotivda?
Like all medicines, Fotivda can cause side effects, although not everyone experiences them. The most serious and most common side effect is high blood pressure (hypertension), which requires regular monitoring. Other common side effects include voice changes, diarrhoea, fatigue, reduced appetite, and hand-foot syndrome.
Side effects are categorised by how frequently they occur. If you experience any side effects that are severe, persistent, or concern you, contact your doctor or oncology team promptly. Some side effects may require dose adjustment, temporary interruption of treatment, or permanent discontinuation of Fotivda.
Very Common
- High blood pressure (hypertension) – the most common and most serious side effect
- Dysphonia (voice changes, hoarseness)
- Diarrhoea
- Loss of appetite, weight loss
- Headache
- Breathlessness, shortness of breath on exertion, cough
- Fatigue, unusual weakness, pain (including mouth, bone, arm, flank, groin, tumour pain)
- Mouth inflammation, nausea, abdominal pain and bloating
- Hand-foot syndrome (redness, swelling, numbness, peeling of palms and soles)
- Back pain
- Tiredness and lack of energy
Common
- Underactive thyroid (hypothyroidism) causing fatigue, lethargy, weight gain, slow heart rate
- Insomnia
- Nerve damage (neuropathy) with tingling, numbness, or weakness in arms and legs
- Visual disturbances including blurred vision
- Rapid heartbeat, chest tightness, heart attack / reduced blood flow to the heart, arterial blood clot
- Pulmonary embolism (blood clot in lungs): cough, chest pain, sudden breathlessness, or coughing up blood
- Deep vein thrombosis (blood clot in leg)
- Very high blood pressure leading to stroke, skin flushing
- Nosebleeds, runny nose, nasal congestion
- Flatulence, heartburn, difficulty swallowing, sore throat, bloated and painful tongue, inflamed or bleeding gums
- Taste changes or loss of taste
- Dizziness, tinnitus, vertigo
- Bleeding (including in the brain, mouth, gums, lungs, stomach, intestines, female genitalia, rectum, adrenal glands)
- Coughing up blood, vomiting blood
- Pallor and tiredness due to blood loss
- Nausea, indigestion, constipation, dry mouth
- Itchy skin, rash, scaling skin, dry skin, hair loss, redness, acne
- Fever, chest pain, swollen feet and legs, chills, low body temperature
- Joint and muscle pain
- Increased protein in urine (proteinuria)
- Abnormal blood test results for liver, pancreas, kidneys, and thyroid
- Pancreatitis (inflammation of the pancreas causing severe abdominal pain radiating to the back)
Uncommon
- Skin rash with pus formation, fungal infections
- Increased bruising tendency, bleeding into the skin
- Overactive thyroid (hyperthyroidism), enlarged thyroid gland
- Increased red blood cell count
- Memory loss
- Temporary reduced blood flow to the brain
- Watery eyes, blocked ears
- Reduced blood flow through the heart’s blood vessels
- Small intestinal ulcer
- Red, swollen, tender skin, blistering, increased sweating, hives
- Muscle weakness
- Swollen or irritated mucous membranes
- Abnormal ECG, rapid and/or irregular heartbeat
- Heart failure (shortness of breath, swollen ankles), fluid accumulation in the lungs
Rare
- Posterior reversible encephalopathy syndrome (PRES): headache, seizures, lack of energy, confusion, blindness or other visual disturbances, or neurological symptoms such as weakness in an arm or leg
Not Known Frequency
- Aneurysm (enlargement and weakening of a blood vessel wall) or arterial dissection (tear in a blood vessel wall)
If you experience any side effects, including those not listed here, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you contribute to the continuous monitoring of this medicine’s benefit-risk balance.
How Should You Store Fotivda?
Keep Fotivda out of the sight and reach of children. Store in the original bottle with the lid tightly closed. The medicine is moisture-sensitive and must be protected from humidity.
Fotivda capsules should be stored in their original HDPE bottle with the child-resistant closure firmly closed at all times when not in use. The capsules are sensitive to moisture, so it is essential to keep the bottle tightly sealed. There are no specific temperature storage requirements beyond normal room conditions.
Do not use Fotivda after the expiry date printed on the carton and bottle label (after “EXP”). The expiry date refers to the last day of the stated month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment.
What Does Fotivda Contain?
Fotivda capsules contain tivozanib as the active substance, available in two strengths: 890 micrograms and 1,340 micrograms. The capsules are visually distinct to help prevent dosing errors.
Fotivda 890 Microgram Hard Capsules
Each capsule contains 890 micrograms of tivozanib (as hydrochloride monohydrate). The 890 microgram capsules have a dark blue opaque cap and a light yellow opaque body. They are printed with “TIVZ” on the cap in yellow ink and “LD” on the body in dark blue ink.
- Capsule contents: mannitol, magnesium stearate
- Capsule shell: gelatin, titanium dioxide (E171), indigo carmine (E132), yellow iron oxide (E172)
- Yellow printing ink: shellac, propylene glycol, concentrated ammonia solution, titanium dioxide (E171), tartrazine (E102)
- Blue printing ink: shellac, propylene glycol, concentrated ammonia solution, indigo carmine aluminium lake (E132)
The yellow printing ink on the Fotivda 890 microgram capsule contains tartrazine (E102), which may cause allergic reactions in some individuals. If you have a known sensitivity to tartrazine or similar azo dyes, inform your doctor before starting treatment.
Fotivda 1,340 Microgram Hard Capsules
Each capsule contains 1,340 micrograms of tivozanib (as hydrochloride monohydrate). The 1,340 microgram capsules have a light yellow opaque cap and a light yellow opaque body. They are printed with “TIVZ” on the cap in dark blue ink and “SD” on the body in dark blue ink.
- Capsule contents: mannitol, magnesium stearate
- Capsule shell: gelatin, titanium dioxide (E171), yellow iron oxide (E172)
- Blue printing ink: shellac, propylene glycol, concentrated ammonia solution, indigo carmine aluminium lake (E132)
Pack Sizes
Both Fotivda 890 microgram and 1,340 microgram capsules are supplied in packs of 21 capsules in HDPE bottles with child-resistant closures. Each bottle contains one treatment cycle’s worth of capsules (21 days of dosing).
Fotivda is manufactured by ALMAC PHARMA SERVICES (IRELAND) LIMITED and marketed by Recordati Netherlands B.V.
Frequently Asked Questions About Fotivda
Fotivda (tivozanib) is used to treat adults with advanced renal cell carcinoma (kidney cancer). It works by blocking VEGF receptors, which cuts off the blood supply to tumours, slowing their growth and spread. It is prescribed when prior cytokine therapy has not been used, or when other systemic treatments have not successfully controlled the disease. The drug was approved by the European Medicines Agency based on clinical trial evidence showing improved progression-free survival.
Fotivda is distinguished by its high selectivity for VEGF receptors (VEGFR-1, -2, and -3) compared with other multi-kinase inhibitors used in kidney cancer (such as sunitinib, pazopanib, or sorafenib), which target multiple different kinase pathways. This selectivity is thought to contribute to a more predictable side effect profile. Additionally, Fotivda uses a unique cyclical dosing schedule (3 weeks on, 1 week off) which may help manage side effects by allowing a recovery period.
High blood pressure is the most common side effect of Fotivda and requires close monitoring. If you develop symptoms such as severe headache, blurred vision, shortness of breath, or confusion, contact your doctor immediately. Your doctor will check your blood pressure regularly and may prescribe antihypertensive medication to control it. In some cases, the Fotivda dose may need to be reduced or treatment temporarily interrupted until blood pressure is under control.
Yes, Fotivda capsules can be taken with or without food. The capsule must be swallowed whole with a glass of water. Do not chew, dissolve, or open the capsule before swallowing. Try to take your dose at approximately the same time each day to maintain consistent drug levels in your body. There are no specific dietary restrictions, although you must avoid St. John’s Wort (Hypericum perforatum) throughout treatment.
The effectiveness of Fotivda was established in the TIVO-3 phase III clinical trial, which compared tivozanib with sorafenib in patients who had received two or three prior systemic therapies for advanced renal cell carcinoma. Tivozanib demonstrated a statistically significant improvement in progression-free survival (5.6 months vs 3.9 months; HR 0.73, p=0.016). Earlier phase III data (TIVO-1 trial) also showed improved PFS versus sorafenib in previously untreated patients (11.9 months vs 9.1 months; HR 0.797, p=0.042).
All information is based on the European Medicines Agency (EMA) approved Summary of Product Characteristics (SmPC) for Fotivda, peer-reviewed publications of the TIVO-1 and TIVO-3 clinical trials, NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer, ESMO Clinical Practice Guidelines for renal cell carcinoma, and WHO Model List of Essential Medicines. All medical claims are supported by Level 1A evidence from randomised controlled trials.
References
- European Medicines Agency (EMA). Fotivda (tivozanib) – Summary of Product Characteristics. Last updated 2023. Available at: www.ema.europa.eu/en/medicines/human/EPAR/fotivda
- Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with treatment-naive advanced renal cell carcinoma: results from the TIVO-1 randomized phase III trial. Lancet Oncol. 2020;21(1):95-104. doi:10.1016/S1470-2045(19)30735-1
- Pal SK, Escudier BJ, Atkins MB, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma after two or three prior systemic therapies: results from the phase III TIVO-3 trial. J Clin Oncol. 2020;38(suppl; abstr 5061).
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2.2024.
- Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706-720. doi:10.1093/annonc/mdz056
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(1):4-34.
Medical Editorial Team
This article has been written by iMedic’s medical editorial team and reviewed by board-certified specialists in oncology and clinical pharmacology. Our editorial process follows the GRADE framework to ensure that all medical claims are supported by the best available evidence.
iMedic Medical Editorial Team – Specialists in oncology, clinical pharmacology, and internal medicine with documented academic background and clinical experience.
iMedic Medical Review Board – Independent panel of medical experts who review all content according to international guidelines (EMA, NCCN, ESMO, WHO).
Evidence Standard: Level 1A – Evidence based on systematic reviews and meta-analyses of randomised controlled trials. All claims are referenced to peer-reviewed publications and regulatory documents.
Conflict of Interest: None. iMedic receives no commercial funding and has no pharmaceutical company sponsorship. All content is editorially independent.
Last Medical Review: